Trial Profile
RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate. A 24-week, Prospective, Open-label, Multicenter Trial Evaluating Treatment Satisfaction in Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment Change From Tecfidera to Rebif 44 mcg Subcutaneously (sc) Three Times Weekly (Tiw)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms RESOunD
- Sponsors EMD Serono
- 03 Jun 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 24 Nov 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
- 21 Apr 2014 New trial record